At Helico, our goal is to unlock the innate ability of plants to become factories for medicinal compounds. Employing innovative research in computational biology and plant physiology, we've packed advanced manufacturing facilities in seeds to produce the world's most needed medicines with low-cost agriculture.
Plants are advanced biological systems. For millennia, humans have relied on the ability of plants to produce useful medicines. Recent advances in genetic engineering help us control the natural abilities of plants and transform them into biological factories. The practice is also called ‘pharming’.
Computational biology tools have come of age. Synthetic biology is a challenging field that requires insight and intuition to produce plausible designs for life-changing drugs or medicine production systems. The development of advanced bioinformatics tools, over the past decade, has accelerated structural biology research and drug discovery programs around the world.
Total Funding: N/A
Funding Stage: N/A
Business Stage: Scaling Up
Market: B2B
Company Size: 1 to 25
Founded: 2020
Nov 2021
- Helico Research is Supported by Callaghan Innovation
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Helico
Nikolai Macnee
Co-founder, Chief Scientific Officer
Xiaoming Wang
Software Developer and Co-founder
Wayman Puna
Chief Technology Officer
Coline Mei
VP Technology & Operation
